Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
ASX data centre share forecasts AI fuelled earnings surge
AI and cloud demand underpin bullish growth outlook
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,301.85 | 32.65 | -0.39% |
| DAX 40 | 25,970.11 | 288.00 | -1.10% |
| Dow JONES (US) | 52,916.89 | 269.01 | -0.51% |
| FTSE 100 | 10,789.28 | 34.98 | -0.32% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,166.61 | 204.28 | -0.77% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,646.77 | 39.37 | -0.51% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |